BLA 761037 · Sanofi Synthelabo
Kevzara
Sarilumab · Injection · Interleukin-6 Receptor Antagonist
NovelLast checked: Nov 20, 2026Latest source record: Jun 10, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
May 22, 2017
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
66
24 Phase 3, 16 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Sarilumab" as an intervention, any sponsor and status, largest first.
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)Pivotal-lookingTerminated
GlaxoSmithKlineGSK (GSK)
NCT04333147 · 2,916 participants · Start May 12, 2020 · Primary completion Feb 24, 2023
Drug: Otilimab (GSK3196165); csDMARD(s) · For: Arthritis, Rheumatoid
Sites: Anniston, Alabama; Flagstaff, Arizona; Gilbert, Arizona · 375 sites in all
- Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT01146652 · 2,023 participants · Start Jun 21, 2010 · Primary completion Dec 31, 2020
Drug: SAR153191 (REGN88) · For: Rheumatoid Arthritis
Sites: Anniston, Alabama; Birmingham, Alabama; Huntsville, Alabama · 335 sites in all
- Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04315298 · 1,912 participants · Start Mar 18, 2020 · Primary completion Jul 24, 2020
Drug: Sarilumab; Placebo · For: COVID-19
Sites: Los Angeles, California; Sacramento, California; Santa Monica, California · 62 sites in all
- Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis PatientsPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT01061736 · 1,675 participants · Start Mar 2010 · Primary completion Oct 2013
Drug: Sarilumab; Placebo (for sarilumab) and 2 more · For: Rheumatoid Arthritis
Sites: Anniston, Alabama; Birmingham, Alabama; Gilbert, Arizona · 262 sites in all
- RA-PRO PRAGMATIC TRIALPivotal-lookingRecruiting
University of Alabama at BirminghamAcademic, hospital or other
NCT04692493 · 924 participants (planned) · Start Sep 22, 2021 · Primary completion May 31, 2029
Drug: targeted synthetic DMARD class; non-TNFi-biologic class · For: Rheumatoid Arthritis
Sites: Auburn, Alabama; Birmingham, Alabama; Peoria, Arizona · 49 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03564340 · 890 participants (planned) · Start May 21, 2018 · Primary completion May 10, 2027
Drug: Ubamatamab; Cemiplimab and 2 more · For: Recurrent Ovarian Cancer; Recurrent Fallopian Tube Cancer; Recurrent Primary Peritoneal Cancer and 3 more
Sites: Birmingham, Alabama; Boston, Massachusetts; Rochester, Minnesota · 54 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Kevzara (Sarilumab)
2024 spending
$172M
Beneficiaries
6,254
37,496 claims
Per beneficiary
$27,534
$1,858.00 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $54,152,208 |
| 2021 | $61,125,620 |
| 2022 | $80,837,227 |
| 2023 | $110,312,728 |
| 2024 | $172,196,864 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
Spiera RF, Unizony S, Warrington KJ, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Kerschbaumer A, Sepriano A, Bergstra SA, et al. · Ann Rheum Dis 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Systematic review and meta-analysis of the efficacy of biologic and targeted synthetic therapies in sarcoidosis.
Bechman K, Biddle K, Miracle A, et al. · Thorax 2025 · Systematic Review, Meta-Analysis
- Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
Gordon AC, Mouncey PR, Al-Beidh F, et al. · N Engl J Med 2021 · Multicenter Study, Randomized Controlled Trial
- Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19.
Khan FA, Stewart I, Fabbri L, et al. · Thorax 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis.
Xu C, Su Y, Paccaly A, et al. · Clin Pharmacokinet 2019 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.